AstraZeneca Commits $100 Million To MedImmune Ventures
This article was originally published in The Pink Sheet Daily
Executive Summary
The UK-based pharma’s corporate venture arm now has $400 million under management in an evergreen fund, with an expanded global focus that includes health care information technology.